Assessment of endothelial (dys)function in atrial fibrillation

References

• Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98: 946–52
   PubMed Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69: 546–54.
   PubMed Web of Science ®Google Scholar
• Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost. 2008; 100: 11–3
   PubMedGoogle Scholar
• Hughes, M, Lip, GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:295–304
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007; 147: 590–2
   PubMed Web of Science ®Google Scholar
• Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009; 373: 155–66
   PubMed Web of Science ®Google Scholar
• Freestone B, Lip GY. The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie. 2008; 28: 207–12
   PubMedGoogle Scholar
• Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol. 2008; 127: 135–7
   PubMed Web of Science ®Google Scholar
• Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des. 2004; 10: 3591–605
   PubMed Web of Science ®Google Scholar
• Castellot JJ, Addonizo ML, Rosenberg RD, Karnowsky MJ. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle growth. J Cell Biol. 1980; 90: 373–9
   Google Scholar
• Rodomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987; 2: 1057–8
   PubMedGoogle Scholar
• Kubes P, Suzukii M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991; 81: 4651–5
   Google Scholar
• Bowie EJW, Solberg LA, Fass DN, Johnson CM, Knutson GJ, Stewart ML, et al. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J Clin Invest. 1986; 78: 26–30
   PubMed Web of Science ®Google Scholar
• Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist?. Br J Haematol. 1995; 90: 244–8
   PubMed Web of Science ®Google Scholar
• Pottinger BE, Read RC, Paleolog EG, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989; 53: 387–94
   PubMed Web of Science ®Google Scholar
• Blann AD. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol. 1991; 50: 320–2
   PubMedGoogle Scholar
• Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995; 345: 152–5
   PubMed Web of Science ®Google Scholar
• Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in non-valvular atrial fibrillation. Stroke. 1990; 21: 47–51
   PubMed Web of Science ®Google Scholar
• Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995; 73: 527–33
   PubMedGoogle Scholar
• Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P, et al. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest. 2008; 133: 1203–8
   PubMedGoogle Scholar
• Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke. 2003; 34: 413–7
   PubMed Web of Science ®Google Scholar
• Lane DA, Lip GY. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost. 2009; 101: 802–5
   PubMed Web of Science ®Google Scholar
• Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000; 31: 828–33
   PubMed Web of Science ®Google Scholar
• Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GY. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J. 2000; 140: 777–84
   PubMed Web of Science ®Google Scholar
• Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001; 37: 1436–42
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003; 111: 137–42
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ikeda U, Seino Y, Mito H, Fujikawa H, Sekiguchi H, et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol. 1995; 25: 107–12
   PubMedGoogle Scholar
• Li-Saw-Hee FL, Blann AD, Goldsmith I, Lip GY. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol. 1999; 83: 1206–9
   PubMed Web of Science ®Google Scholar
• Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997; 77: 407–11
   PubMed Web of Science ®Google Scholar
• Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003; 107: 3141–5
   PubMed Web of Science ®Google Scholar
• Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willbrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002; 106: 1962–7
   PubMed Web of Science ®Google Scholar
• Jansson J, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991; 66: 351–5
   PubMedGoogle Scholar
• Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006; 37: 2294–300
   PubMed Web of Science ®Google Scholar
• McDermott JR. Studies on the catabolism of Ng-methyl arginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J. 1976; 154: 179–84
   PubMed Web of Science ®Google Scholar
• Cooke JP. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol. 2000; 20: 2032–7
   PubMed Web of Science ®Google Scholar
• Cooke JP. Asymmetrical dimethyl arginine: the uber marker?. Circulation. 2004; 109: 1813–8
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al. Asymmetrical dimethyl arginine, an endogenous nitric oxide synthase inhibitor in experimental hypertension. Hypertension. 1997; 29: 242–7
   PubMed Web of Science ®Google Scholar
• Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with Type 2 diabetes mellitus. Am J Cardiol. 2001; 88: 1201–3
   PubMed Web of Science ®Google Scholar
• Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetrical dimethyl arginine (ADMA): a novel risk factor for endothelial function: its role in hypercholesterolemia. Circulation. 1998; 98: 1842–7
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999; 99: 1141–6
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Claver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992; 339: 572–5
   PubMed Web of Science ®Google Scholar
• Cengel A, Sahinarslan A, Biberoğlu G, Hasanoğlu A, Tavil Y, Tulmaç M, et al. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol. 2008; 63: 33–7
   PubMed Web of Science ®Google Scholar
• Xia W, Qu X, Yu Y, Zhang X, Feng W, Song Y. Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol. 2008; 31: 1036–40
   PubMed Web of Science ®Google Scholar
• Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993; 14: 506–12
   PubMedGoogle Scholar
• Blann AS, Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanism and clinical implications. Blood Coagul Fibrinolysis. 1998; 9: 297–306
   PubMed Web of Science ®Google Scholar
• Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991; 251: 788–91
   PubMed Web of Science ®Google Scholar
• Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of soluble adhesion molecule E-selectin in essential hypertension. 1994; 12: 925–8
   Google Scholar
• Blann AS, Waite MA. von Willebrand factor and solute E-selectin in hypertension. Influence of treatment value in predicting the progression of atherosclerosis. Coron Artery Dis. 1996; 7: 143–7
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001; 104: 1336–42
   PubMed Web of Science ®Google Scholar
• Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 2001; 37: 2392–7
   PubMed Web of Science ®Google Scholar
• Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest. 2007; 132: 1253–8
   PubMed Web of Science ®Google Scholar
• Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007; 99: 1544–8
   PubMed Web of Science ®Google Scholar
• Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res. 2008; 122: 85–90
   PubMed Web of Science ®Google Scholar
• Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, et al. Circulating endothelial cells: Biomarker of vascular disease. Thromb Haemostat. 2005; 93: 228–35
   PubMed Web of Science ®Google Scholar
• Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood. 1999; 93: 2951–8
   PubMed Web of Science ®Google Scholar
• Nadar SK, Lip GYH, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic strokes. Thromb Haemost. 2005; 94: 707–12
   PubMed Web of Science ®Google Scholar
• Bull TM, Golpon H, Hebbel RP, Solovey A, Cool CD, Tuder RM, et al. Circulating endothelial cells in pulmonary hypertension. Thromb Haemost. 2003; 90: 698–703
   PubMed Web of Science ®Google Scholar
• Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anaemia. N Engl J Med. 1997; 337: 1584–90
   PubMed Web of Science ®Google Scholar
• Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet. 2003; 361: 206–10
   PubMed Web of Science ®Google Scholar
• Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004; 110: 1794–8
   PubMed Web of Science ®Google Scholar
• Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6 and prognosis in patients with acute coronary syndromes. Blood. 2005; 105: 526–32
   PubMed Web of Science ®Google Scholar
• Freestone B, Lip GY, Chong AY, Nadar S, Lee KW, Blann AD. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost. 2005; 94: 702–6
   PubMed Web of Science ®Google Scholar
• Goette A, Jentsch-Ullrich K, Lendeckel U, Roken C, Agbaria M, Auricchio A, et al. Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide. Circulation. 2003; 108: 2446–9
   PubMed Web of Science ®Google Scholar
• Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation?. Arterioscler Thromb Vasc Biol. 2006; 26: 2594–604
   PubMed Web of Science ®Google Scholar
• Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease?. Eur J Clin Invest. 2004; 34: 392–401
   PubMed Web of Science ®Google Scholar
• Mallat Z, Hugel B, Ohan J, Lesèche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999; 99: 348–53
   PubMed Web of Science ®Google Scholar
• Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001; 104: 2649–52
   PubMed Web of Science ®Google Scholar
• Morel O, Hugel B, Jesel L, Lanza F, Douchet MP, Zupan M, Chauvin M, Cazenave JP, Freyssinet JM, Toti F. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost. 2004; 91: 345–53
   PubMedGoogle Scholar
• Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multi infarct dementias. Thromb Res. 1993; 72: 295–304
   PubMed Web of Science ®Google Scholar
• Ederhy S, Di Angelantonio E, Mallat Z, Hugel B, Janower S, Meuleman C, et al. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation. Am J Cardiol. 2007; 100: 989–94
   PubMed Web of Science ®Google Scholar
• Sadler JE. Thrombomodulin structure and function. Thromb Haemost. 1997; 78: 392–5
   PubMed Web of Science ®Google Scholar
• Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 1995; 9: 946–55
   PubMed Web of Science ®Google Scholar
• Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest. 1985; 76: 2178–81
   PubMed Web of Science ®Google Scholar
• Erdem Y, Usalan C, Haznedaroğlu IC, Altun B, Arici M, Yasavul U, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens. 1999; 12: 1071–6
   PubMed Web of Science ®Google Scholar
• Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Clinical significance of measurements of urinary and serum thrombomodulin in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1996; 33: 99–104
   PubMedGoogle Scholar
• Blann AD, Admiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol. 1997; 59: 115–20
   PubMed Web of Science ®Google Scholar
• Constans J, Blann AD, Renard M, Guérin V, Conri C. Soluble thrombomodulin in hypercholesterolaemic patients. Lancet. 2000; 355: 145
   PubMedGoogle Scholar
• Gris JC, Branger B, Vécina F, al Sabadani B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int. 1994; 46: 807–13
   PubMed Web of Science ®Google Scholar
• Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 1999; 353: 1729–34
   PubMed Web of Science ®Google Scholar
• Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R, et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic non-rheumatic atrial fibrillation. Int J Cardiol. 2000; 75: 227–32
   PubMed Web of Science ®Google Scholar
• Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39: 257–65
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995; 26: 1235–41
   PubMed Web of Science ®Google Scholar
• Matsuo S, Matsumoto T, Takashima H, Ohira N, Yamane T, Yasuda Y, et al. The relationship between flow-mediated brachial artery vasodilation and coronary vasomotor responses to bradykinin: comparison with those to acetylcholine. J Cardiovasc Pharmacol. 2004; 44: 164–70
   PubMedGoogle Scholar
• Teragawa H, Ueda K, Matsuda K, Kimura M, Higashi Y, Oshima T, et al. Relationship between endothelial function in the coronary and brachial arteries. Clin Cardiol. 2005; 8: 460–6
   Google Scholar
• Deng YB, Wang XF, Le GR, Zhang QP, Li CL, Zhang YG. Evaluation of endothelial function in hypertensive elderly patients with high-resolution ultrasonography. Clin Cardiol. 1999; 22: 705–10
   PubMed Web of Science ®Google Scholar
• Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium dependent and independent dilatation of forearm resistance arteries in men with diet treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Colch) 1996; 91: 567–73
   Google Scholar
• Takase B, Uehata A, Akima T. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998; 82: 1535–9
   PubMed Web of Science ®Google Scholar
• Stroes ES, Koomans HA, De Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemia patients off and on lipid-lowering medication. Lancet. 1995; 346: 467–71
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Spiegelhalter DJ, Geroggakapoulos D, Robinson J, Deanfield JE. Ageing is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994; 24: 471–6
   PubMed Web of Science ®Google Scholar
• van der Heijden-Spek JJ, Staessen JA, Fagard RH, Hoeks AP, Boudier HA, van Bortel LM. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study. Hypertension. 2000; 35: 637–42
   PubMed Web of Science ®Google Scholar
• Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Celermajer DS. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann Intern Med. 1999; 130: 578–81
   PubMed Web of Science ®Google Scholar
• O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95: 1126–31
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, et al. Effect of treatment on flow-dependent vasodilatation of the brachial artery in essential hypertension. Hypertension. 1999; 33: 575–80
   PubMed Web of Science ®Google Scholar
• Skalidis EI, Zacharis EA, Tsetis DK, Pagonidis K, Chlouverakis G, Yarmenitis S, et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol. 2007; 99: 1258–62
   PubMed Web of Science ®Google Scholar
• Guazzi M, Belletti S, Lenatti L, Bianco E, Guazzi MD. Effects of cardioversion of atrial fibrillation on endothelial function in hypertension or diabetes. Eur J Clin Invest. 2007; 37: 26–34
   PubMed Web of Science ®Google Scholar
• Collins P. Coronary flow reserve. Br Heart J. 1993; 69: 279–81
   PubMedGoogle Scholar
• Gullu H, Erdogan D, Caliskan M, Tok D, Yildirim E, Ulus T, et al. Interrelationship between noninvasive predictors of atherosclerosis: transthoracic coronary flow reserve, flow-mediated dilation, carotid intima-media thickness, aortic stiffness, aortic distensibility, elastic modulus, and brachial artery diameter. Echocardiography. 2006; 3: 35–42
   Google Scholar
• Pellegrino T, Storto G, Filardi PP, Sorrentino AR, Silvestro A, Petretta M, et al. Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. J Nucl Med. 2005; 46: 1997–2002
   PubMed Web of Science ®Google Scholar
• Marcus M, Wright C, Doty D, Eastham C, Laughlin D, Krumm P, et al. Measurements of coronary velocity and reactive hyperemia in the coronary circulation of humans. Circ Res. 1981; 49: 877–91
   PubMed Web of Science ®Google Scholar
• Felder L, Vassalli G, Vassalli F, Jiang Z, Grimm J, Krayenbuehl HP, et al. Clinical significance of coronary flow reserve: effect of papaverine and exercise. Coron Artery Dis. 1994; 5: 347–58
   PubMedGoogle Scholar
• Christensen CW, Rosen LB, Gal RA, Hasseb M, Lassar TA, Port SC. Coronary vasodilator reserve. Comparison of the effects of papaverine and adenosine on coronary flow, ventricular function and myocardial metabolism. Circulation. 1991; 83: 294–303
   PubMed Web of Science ®Google Scholar
• Rossen JD, Quillen JE, Lopez AG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol. 1991; 18: 485–91
   PubMedGoogle Scholar
• Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG. Understanding the coronary circulation through studies at the microvascular level. Circulation. 1990; 82: 1–7
   PubMed Web of Science ®Google Scholar
• Olsen MH, Wachtell K, Meyer C, Hove JD, Palmieri V, Dige-Petersen H, et al. Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy. J Hum Hypertens. 2004; 18: 445–52
   PubMedGoogle Scholar
• Nahser PJ, Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation. 1995; 91: 635–40
   PubMedGoogle Scholar
• Selke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic patients. Circulation. 1990; 81: 1586–93
   PubMedGoogle Scholar
• Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stage of coronary atherosclerosis. Circulation. 1991; 83: 391–401
   PubMed Web of Science ®Google Scholar
• Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation. 1996; 94: 3232–8
   PubMed Web of Science ®Google Scholar
• Tok D, Gullu H, Erdogan D, Topcu S, Ciftci O, Yildirim I, et al. Impaired coronary flow reserve in hemodialysis patients: a transthoracic Doppler echocardiographic study. Nephron Clin Pract. 2005; 101: c200–6
   PubMedGoogle Scholar
• Ashikaga T, Nishizaki M, Fujii H, Niki S, Maeda S, Yamawake N, et al. Examination of the microcirculation damage in smokers versus nonsmokers with vasospastic angina pectoris. Am J Cardiol. 2007; 100: 962–4
   PubMedGoogle Scholar
• Sulli A, Ghio M, Bezante GP, Deferrari L, Craviotto C, Sebastiani V, et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 505–9
   PubMedGoogle Scholar
• Hirata K, Kadirvelu A, Kinjo M, Sciacca R, Sugioka K, Otsuka R, et al. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum. 2007; 56: 1904–9
   PubMedGoogle Scholar
• Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 1899–906
   PubMed Web of Science ®Google Scholar
• Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948–54
   PubMed Web of Science ®Google Scholar
• Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol. 2008; 51: 2053–7
   PubMed Web of Science ®Google Scholar
• Range FT, Schäfers M, Acil T, Schäfers KP, Kies P, Paul M, et al. Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur Heart J. 2007; 28: 2223–30
   PubMedGoogle Scholar
• Takahashi N, Ishibashi Y, Shimada T, Sakane T, Ohata S, Sugamori T, et al. Atrial fibrillation impairs endothelial function of forearm vessels in humans. J Card Fail. 2001; 7: 45–54
   PubMed Web of Science ®Google Scholar
• Takahashi N, Ishibashi Y, Shimada T, Sakane T, Ohata S, Sugamori T, et al. Impaired exercise-induced vasodilatation in chronic atrial fibrillation—role of endothelium-derived nitric oxide. Circ J. 2002; 66: 583–8
   PubMedGoogle Scholar
• Freestone B, Chong AY, Blann AD, Lip GY. The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction. Thromb Res. 2006; 118: 479–85
   PubMedGoogle Scholar
• Freestone B, Chong AY, Lim HS, Blann A, Lip GY. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?. Ann Med. 2005; 37: 365–72
   PubMed Web of Science ®Google Scholar
• Lip GY, Pearce LA, Chin BS, Conway DS, Hart RG. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvular atrial fibrillation. Heart. 2005; 91: 759–63
   PubMedGoogle Scholar
• Marin F, Roldan V, Climent VE, Ibanez A, Garcia A, Marco P, et al. Plasma von Willebrand factor, soluble thrombomodulin and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart. 2004; 90: 1162–6
   PubMed Web of Science ®Google Scholar
• Goette A, Weber M, Lendenckel U, Welte T, Lutze G, Klein HU. Effect of physical exercise on platelet activity and the von Willebrand factor in patients with persistent atrial fibrillation. J Interv Card Electrophysiol. 2004; 10: 139–46
   PubMedGoogle Scholar
• Roldan V, Marin F, Blann AD, Garcia A, Marco P, Sogrob F, Lip GY. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J. 2003; 24: 1373–80
   PubMed Web of Science ®Google Scholar
• Nikitovic D, Zacharis EA, Manios EG, Malliaraki NE, Kanoupakis EM, Sfiridaki KI, et al. Plasma levels of nitrites/nitrates in patients with chronic atrial fibrillation are increased after electrical restoration of sinus rhythm. J Interv Card Electrophysiol. 2002; 7: 171–6
   PubMedGoogle Scholar
• Feng D, D'Agostino RB, Silbershatz H, Lipinska I, Massaro J, Levy D, et al. Hemostatic state ad atrial fibrillation (the Framingham Offspring Study). Am J Cardiol. 2001; 87: 168–71
   PubMed Web of Science ®Google Scholar
• Li Saw Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001; 22: 1741–7
   PubMedGoogle Scholar